Advertisement

Topics

Cellectis doses first patient with BPDCN in phase I study of UCART123

07:00 EDT 20 Aug 2017 | PharmaBiz

Cellectis, a clinical─stage biopharmaceutical company focused on developing immunotherapies based on gene─edited CAR T─cells (UCART), announced that the first patient with Blastic Plasmacytoid

Original Article: Cellectis doses first patient with BPDCN in phase I study of UCART123

NEXT ARTICLE

More From BioPortfolio on "Cellectis doses first patient with BPDCN in phase I study of UCART123"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...